Quick Facts

• Targeted Relief: Supports the reduction of symptoms associated with seasonal and year-round allergies.
• Chronic Condition Support: Provides management for chronic hives.

Lergicare is an approved agent used to address symptoms linked to various allergic conditions in adults and children (age-appropriate doses apply). The primary therapeutic domains for this treatment involve minimizing discomfort and distress caused by histamine-related reactions.

The drug is administered for the management of symptoms associated with allergic rhinitis, commonly referred to as hay fever. This includes the alleviation of red, itchy, or watery eyes, a runny nose, and sneezing that may be prompted by seasonal environmental triggers or perennial exposure.

Additionally, Lergicare may contribute to the reduction of symptoms related to chronic idiopathic urticaria (hives), which is characterized by long-lasting, recurring skin welts and itching. Through its approved mechanism, it supports the body’s response to the underlying condition, helping to maintain comfort and routine daily activity.

Who Can and Cannot Use Lergicare?

Eligibility for Lergicare is defined by official regulatory documentation, primarily based on age, kidney function, and known allergies. The medicine is contraindicated and must not be used by anyone with a known hypersensitivity to levocetirizine, cetirizine, or any related compounds. Use is also strictly prohibited in patients with end-stage renal disease (creatinine clearance below 10 mL/min) and those undergoing hemodialysis.

Age-Related Eligibility

Lergicare is approved for adults and adolescents 12 years of age and older. The oral solution is approved for children as young as 6 months of age for certain indications, while the tablet formulation is typically reserved for children 6 years and older. Use is formally not established in infants under 6 months of age, and children 6 months to 11 years old with any impaired renal function are contraindicated from using the medicine.

Condition-Based Restrictions

For adults and adolescents with mild to severe non-end-stage renal impairment, eligibility is conditional and requires a prescribed adjustment to the regimen. Caution is also advised for patients with predisposing factors for urinary retention, such as prostatic hyperplasia.

Pregnancy and Lactation

Official labeling advises that pregnant women should consult a health professional before use. Use is officially not recommended for mothers who are breastfeeding.

Interactions with other medicines and products

Official regulatory documentation structures Lergicare's (Levocetirizine) interaction profile around effects on elimination and the Central Nervous System (CNS).

---

Interaction Scope

Category	Documented Interaction Entities and Restrictions
Contraindicated Combinations	– Patients with End-Stage Renal Disease (creatinine clearance < 10 mL/min) and patients undergoing hemodialysis.
– Pediatric patients (6 months to 11 years) with impaired renal function are also contraindicated.
Pharmacodynamic Interactions	– Alcohol and other CNS Depressants: Concurrent use is officially noted to cause an additive effect resulting in additional impairment of CNS performance and reduced alertness.
Exposure-Modifying Substances	– Ritonavir: Co-administration with the racemate, Cetirizine, was documented to increase the antihistamine's systemic exposure (AUC) and reduce its total body clearance.
– Theophylline: Co-administration with a 400 mg dose of theophylline caused a small decrease in clearance of the racemate, Cetirizine.
Metabolic / Timing	– CYP Enzymes: In vitro data suggests Levocetirizine is unlikely to produce or be subject to significant metabolic interactions.
– Timing: No mandatory timing separation requirements for co-administration are documented in the official regulatory labels.

---

Connection to the Overall Interaction Profile

Regulatory documentation defines Lergicare's core interaction structure by two primary concerns: the pharmacodynamic reinforcement of depressant effects with substances like alcohol, and the importance of the renal elimination pathway. The reliance on kidney function results in formal contraindications for patients with severe renal impairment to prevent drug accumulation and heightened systemic exposure. Specific drugs, such as Ritonavir and Theophylline, have been officially studied to demonstrate a clinically relevant effect on the antihistamine's clearance.

How Lergicare Works

Lergicare employs a dual mechanism of action centered on modulating the immediate hypersensitivity pathway. Its primary function involves acting as a competitive antagonist at the Histamine H1-receptors, which are expressed on various cell surfaces, including endothelial cells and sensory neurons. By binding to these receptors, the drug blocks the signaling cascade normally initiated by the endogenous molecule, histamine. This targeted interference modifies the molecular steps that mediate capillary dilation and neural activation, resulting in altered nerve signaling patterns and modification of peripheral vascular permeability.

Additionally, Lergicare engages a distinct mechanism by acting as a stabilizer on mast cells. This interaction reduces the propensity of mast cells to degranulate upon stimulus, thereby limiting the acute release of stored inflammatory mediators into the surrounding tissue. By influencing both the receptor activation (blockade) and the mediator source (stabilization), the drug contributes to modification of the peripheral inflammatory cascade.

How to Use Lergicare: Administration Guidelines

Lergicare (levocetirizine) is an oral medication with administration protocols used to ensure consistent and appropriate use. The dosage and frequency are standardized, though they are adjusted for specific patient populations. The medication is available as an oral tablet and an oral solution.

---

Administration Scope

Feature	Instruction
Route of administration	Oral intake only.
Standard Dosing Schedule	The standard adult dose is 5 mg administered once daily. Dosing may be taken without regard to food consumption.
Administration Timing	Recommended to be taken in the evening as a single daily intake.
Preparation Requirements	Oral tablets should be swallowed whole. The oral solution must be accurately measured using a proper dosing device to ensure correct volume.
Missed-Dose Rule	Take the missed dose as soon as remembered; if close to the next scheduled dose, skip the missed one and return to the regular schedule. Do not double the dose.

---

Population-Specific Dosing Rules

Dose adjustments are based on age and kidney function, as the drug is primarily eliminated by the kidneys.

• Pediatric Dosing (Ages 6–11): The maximum recommended dose is 2.5 mg once daily.
• Renal Impairment: For adults and children 12 years and older, dosing intervals are individualized based on creatinine clearance. For moderate renal impairment, a reduced frequency (e.g., 2.5 mg every other day) is required.

These instructions define the standardized approach for using Lergicare, ensuring consistency with standard parameters.

Lergicare: Recent Clinical Evidence

Lergicare's active ingredient, levocetirizine, is a selective, second-generation H1-receptor antagonist. Clinical evidence from randomized, placebo-controlled studies supports its efficacy and safety for treating symptoms associated with seasonal and perennial allergic rhinitis (hay fever) and chronic idiopathic urticaria (hives of unknown cause).

Clinical trials have demonstrated that a once-daily dose of levocetirizine is significantly more effective than a placebo in reducing key symptoms such as sneezing, runny nose, itchy eyes, and the severity and duration of pruritus (itching) and wheals associated with hives. The compound is the active enantiomer of cetirizine, and studies indicate it has a high affinity for the peripheral H1 receptor.

Safety and Tolerability

As a second-generation antihistamine, levocetirizine is designed to have minimal ability to cross the blood-brain barrier, which contributes to its generally favorable safety profile regarding sedation compared to older antihistamines. The most commonly reported side effects in clinical trials are typically mild and include somnolence (drowsiness), fatigue, and dry mouth. In line with international guidelines, levocetirizine is widely recommended as a first-line treatment for these allergic conditions.

Indication	Demonstrated Efficacy in Clinical Trials
Allergic Rhinitis	Significant reduction in nasal and non-nasal symptoms (e.g., sneezing, rhinorrhea, ocular itching).
Chronic Urticaria	Effective in decreasing the number and size of wheals, as well as the severity and duration of pruritus.

Patients with moderate to severe kidney impairment should be cautiously managed, and a dose adjustment may be necessary due to levocetirizine's primary route of excretion being through the kidneys. There are also post-marketing reports of severe pruritus (itching) upon discontinuation, typically following long-term use.

Common questions about Lergicare (FAQ)

Q: Is Lergicare meant for both indoor and outdoor allergy symptoms?

Official information states that Lergicare is indicated for the relief of symptoms associated with both seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR). Therefore, the medication is approved for relief of symptoms associated with conditions that involve both indoor and outdoor allergens.

Q: Are the core ingredients in Lergicare similar to common over-the-counter allergy tablets?

The active ingredient in Lergicare is levocetirizine. This substance is the single, active component of the widely known second-generation antihistamine, cetirizine.

Q: How long does the anti-allergy effect of Lergicare usually last?

Studies and official information indicate that Lergicare provides significant antihistaminic activity for a duration of up to 28 hours after a single dose.

Q: Is Lergicare designed for long-term daily use?

Regulatory documents indicate Lergicare is approved for conditions like Chronic Idiopathic Urticaria (CIU), which is a long-lasting condition. Warnings about severe itching upon discontinuation are associated with use over many months to years, indicating that daily use for long periods is an established use context.

Q: Does Lergicare commonly cause side effects like dry mouth or dizziness?

Dry mouth is listed as a common adverse reaction in adults taking Lergicare. While dizziness may occur, official warnings note that this effect is more likely when Lergicare is taken in combination with alcohol or other medicines that affect the central nervous system.

Q: Does Lergicare have the potential to affect concentration or mental clarity?

Lergicare may cause somnolence (drowsiness) and reduced alertness. These effects are related to the drug's action on the central nervous system, where focus and alertness are governed.

Q: Is it safe to take Lergicare with alcohol?

Concurrent use of Lergicare with alcohol or other Central Nervous System (CNS) depressants is advised against in the official label. This combination may lead to additive CNS impairment and a reduction in alertness.

Q: What is known about the long-term effects of taking Lergicare regularly?

The main long-term safety observation noted in official documents is the risk of new onset severe pruritus (itching). This may occur within a few days of stopping the medicine, typically following long-term daily use (e.g., few months to years).

Q: Is there a lot of research evidence supporting the use of Lergicare?

Studies and official information indicate that the effectiveness and safety of Lergicare are supported by evidence from well-conducted, randomized, placebo-controlled clinical trials. These studies demonstrate its benefit for both allergic rhinitis and chronic hives.

Q: Is Lergicare a type of decongestant medicine?

Lergicare is formally classified as an antihistamine. Some clinical data suggests the drug may modify symptoms like nasal obstruction in allergic rhinitis, but it is not formally classified or approved as a decongestant.

Q: How long does Lergicare typically take before the effects start?

Clinical data indicates that Lergicare is rapidly absorbed. The onset of action, where the initial effects begin, generally occurs within 1 hour of a single dose.

Q: Is Lergicare something that loses effectiveness over time with repeated use?

The official regulatory label does not specifically address a loss of effectiveness (sometimes called tolerance or tachyphylaxis). However, general medical literature suggests that tolerance may be a possibility with the chronic, continuous use of some antihistamines.

Q: Can Lergicare be taken only when allergy symptoms appear, as described in official documents?

Official regulatory information for Lergicare focuses on a once-daily dosing schedule for the continuous relief of symptoms associated with chronic and seasonal conditions.

Q: What is the usual time frame for Lergicare to reach its full benefit?

Although initial relief begins quickly, it may take a few days of regular administration to approach the full therapeutic benefit. This may be more noticeable for the persistent symptoms of allergies, such as nasal congestion.

Q: Is Lergicare described as having the potential for drug dependency?

The official label does not associate the medication with drug abuse or dependency. While reports of withdrawal symptoms, such as severe itching, may follow long-term discontinuation, these are not classified as drug dependency.

Q: Is there information about what to do if a possible side effect occurs while taking Lergicare?

Official safety information states that patients are advised to contact a healthcare professional immediately if they experience severe symptoms or side effects. This includes signs of an allergic reaction or trouble passing urine.

Q: Is there an official black box warning associated with Lergicare?

Lergicare (levocetirizine) does not currently have a Boxed Warning (often called a Black Box Warning) in its official FDA prescribing information.

Q: Does Lergicare interact with common pain relief medicines like ibuprofen?

Major drug interaction databases do not list specific known interactions between levocetirizine and common nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen.

Q: Are there specific types of over-the-counter drugs that should not be taken with Lergicare?

Official warnings advise caution or avoidance with alcohol and any other over-the-counter medicines that cause drowsiness or act as Central Nervous System (CNS) depressants. This is due to the potential for compounded effects on alertness.

Q: Can Lergicare be used at the same time as a corticosteroid nasal spray?

There are no known pharmacological contraindications, and regulatory interaction checkers typically do not flag an issue. This combination is widely described in medical literature as a strategy for comprehensive allergy relief.

Q: Does Lergicare interact with medications for high blood pressure?

Official information suggests that antihistamines not containing a decongestant, such as Lergicare, are typically suitable for concurrent use with most blood pressure medications. However, some specific drug combinations may increase the chance of drowsiness.

Q: Are there known interactions between Lergicare and herbal supplements?

Regulatory bodies advise patients to inform their healthcare provider about all prescription, non-prescription, and herbal products they are using before starting Lergicare. This recommendation is a standard measure for managing potential interactions.

Q: Can Lergicare be used to help with motion sickness?

Lergicare is indicated only for the relief of symptoms associated with allergic rhinitis (hay fever) and chronic hives. It is not indicated or approved by regulatory agencies for the treatment or prevention of motion sickness.

How to Store and Dispose of Lergicare

Lergicare (levocetirizine) must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F), with temporary excursions permitted from 15 C to 30 C (59 F to 86 F). To maintain product integrity, the medicine must be stored in its original container and protected from moisture.

All forms of Lergicare must be stored out of the sight and reach of children.

Disposal Requirements

The preferred method for discarding unused or expired Lergicare is through an official drug take-back program or mail-back service. If a take-back option is not available, the product can be mixed with an undesirable substance (such as dirt) and placed in a sealed container before being thrown into the household trash. The product should not be flushed down the toilet.